Recent chatter on X about Tempus AI, Inc. (TEM) has been lively, with much of the focus on the company’s raised 2025 financial outlook, including boosted revenue and EBITDA projections. Many users are pointing to strong quarterly results and strategic partnerships as key drivers of this optimism. The discussion reflects a renewed interest in the stock’s potential as it continues to gain traction in the AI-driven healthcare space.
However, not all sentiment is uniformly positive, as some conversations have revisited a past short report that questioned the company’s revenue sources and leadership practices, causing significant price drops earlier this year. Despite this, a number of users on X argue that the negative impact of such reports may already be reflected in the current price, with several highlighting technical breakouts and potential upside targets. This mix of perspectives keeps the dialogue around TEM dynamic and closely watched.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI, Inc. Insider Trading Activity
Tempus AI, Inc. insiders have traded $TEM stock on the open market 211 times in the past 6 months. Of those trades, 0 have been purchases and 211 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 70 sales selling 5,531,317 shares for an estimated $332,448,701.
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 20 sales selling 128,151 shares for an estimated $9,802,522.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 27 sales selling 112,835 shares for an estimated $8,249,522.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 23 sales selling 110,802 shares for an estimated $6,616,383.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 23 sales selling 88,183 shares for an estimated $5,852,572.
- SCOTT GOTTLIEB has made 0 purchases and 9 sales selling 55,675 shares for an estimated $2,674,142.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 10 sales selling 32,580 shares for an estimated $2,186,740.
- JENNIFER A DOUDNA has made 0 purchases and 8 sales selling 11,811 shares for an estimated $642,886.
- WAYNE A.I. FREDERICK has made 0 purchases and 6 sales selling 12,000 shares for an estimated $576,278.
- NADJA WEST has made 0 purchases and 10 sales selling 8,443 shares for an estimated $414,309.
- DAVID R EPSTEIN has made 0 purchases and 4 sales selling 1,980 shares for an estimated $99,681.
- THEODORE LEONSIS sold 770 shares for an estimated $51,020
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI, Inc. Government Contracts
We have seen $5,785,617 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TUMOR NORMAL MATCHED GENOMIC TESTING SERVICES: $5,718,045
- DNA METHYLATION SERVICES FOR TELECONFERENCING EXERCISE STUDY IN HIV + PATIENTS: $67,572
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 06/30/2025
- Morgan Stanley issued a "Overweight" rating on 05/09/2025
- Needham issued a "Buy" rating on 05/07/2025
- BTIG issued a "Buy" rating on 04/21/2025
- TD Cowen issued a "Buy" rating on 02/05/2025
To track analyst ratings and price targets for Tempus AI, Inc., check out Quiver Quantitative's $TEM forecast page.
Tempus AI, Inc. Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 8 analysts offer price targets for $TEM in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Subbu Nambi from Guggenheim set a target price of $75.0 on 06/30/2025
- Michael Ryskin from B of A Securities set a target price of $70.0 on 06/25/2025
- David Westenberg from Piper Sandler set a target price of $70.0 on 05/15/2025
- Tejas Savant from Morgan Stanley set a target price of $65.0 on 05/09/2025
- Ryan MacDonald from Needham set a target price of $70.0 on 05/07/2025
- Mark Massaro from BTIG set a target price of $60.0 on 04/21/2025
- Rachel Vatnsdal from JP Morgan set a target price of $55.0 on 02/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
